PT-141, also known as bremelanotide, is a synthetic peptide studied for its interaction with melanocortin receptors in the central nervous system. This article provides an educational overview of what the published scientific literature reports about PT-141, its structure, and its mechanisms of interest. All information below is provided strictly for research and informational purposes.
What is PT-141?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide — a seven-amino-acid chain — developed as a structural analogue of alpha-melanocyte-stimulating hormone (α-MSH). Research literature notes it was derived from Melanotan II and developed by Palatin Technologies as a more targeted melanocortin receptor agonist. It is typically supplied as a lyophilised powder for research use.
Mechanisms of interest
Scientific interest in PT-141 centres on its activity within the melanocortin receptor system. The melanocortin system comprises five G protein-coupled receptor subtypes (MC1R through MC5R), each with distinct tissue distribution. The published literature describes PT-141's study in relation to:
- MC3R and MC4R agonism — PT-141 shows preferential activity at these two subtypes, which are the most densely expressed in hypothalamic and limbic brain regions.
- Central rather than peripheral action — research consistently notes that PT-141 engages receptors in the brain rather than acting directly on vascular tissue, mechanistically distinguishing it from peripherally-acting compounds such as PDE5 inhibitors.
- Intracellular signalling — MC4R binding is described as triggering Gs-protein coupling, adenylyl cyclase activation and cAMP elevation, with secondary involvement of PLC and ERK/MAPK pathways in neuronal populations.
- Neuroendocrine research — the melanocortin system is also studied in relation to energy regulation, inflammatory signalling, and reproductive neuroendocrinology, including MC4R's role in GnRH pulsatility.
What the research has reported
PT-141 has one of the more extensively documented research profiles among peptides in this category, spanning preclinical and clinical work. Animal model research has examined neural circuit mechanisms, including c-Fos immunoreactivity in the paraventricular nucleus and findings in MC4R knockout models. Clinical research programmes have progressed through multiple phases. Researchers note that translation of specific neural circuit findings from animal models to human physiology requires confirmation, and that isolating subtype-specific effects (MC3R versus MC4R) requires additional research tools given PT-141's activity at both.
Regulatory status in Australia
Bremelanotide holds regulatory approval in certain overseas markets for a specific medical indication. However, approval in one country does not constitute approval in another, and material supplied for laboratory research is a separate matter from any approved pharmaceutical product.
Research-grade PT-141 is supplied strictly as a research compound and is not an approved therapeutic good in Australia. Anyone seeking treatment for a medical condition should speak with a qualified medical practitioner about approved options available in Australia.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. PT-141 is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption and is not a substitute for any approved medicine. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.